Polymerase chain reaction

The Worldwide Hepatitis C Testing Industry is Projected to Reach $2.2 Billion by 2031 at a 5.3% CAGR

Retrieved on: 
Tuesday, January 24, 2023
NIB, Immunoassay, Hepatitis C, Liver, Infection, Viral, Hepatitis, National Institute for Biological Standards and Control, Hepatitis B, Blood, Illumina, Inc., PerkinElmer, PCR, ELISA, Syphilis, FDA, Porter's five forces analysis, Growth, Benchmarking, Prevalence, HCV, Abbott Laboratories, Laboratory, World Health Organization, WHO, Blood transfusion, Polymerase chain reaction, HIV, Thermo Fisher Scientific, Pharmaceutical industry, Vaccine, Marketing

The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.

Key Points: 
  • The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.
  • The increasing rate of hepatitis C and rise in awareness about hepatitis C drives the growth of market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis c testing market analysis from 2021 to 2031 to identify the prevailing hepatitis c testing market opportunities.
  • The report includes the analysis of the regional as well as global hepatitis c testing market trends, key players, market segments, application areas, and market growth strategies.

Global and Regional Molecular Oncology Diagnostics Market Report 2022: Analysis and Forecasts, 2021-2032 - Launch of Innovative Products in Molecular Oncology Diagnostics Ecosystem - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Health, General Health, Hospital, QIAGEN, Name, Agilent Technologies, Cancer, CRC, Library, Lymphatic system, Esophageal cancer, NGS, Colorectal cancer, Laboratory, Becton, Breast, Region, Bio-Rad Laboratories, Liquid biopsy, B-cell lymphoma, Polymerase chain reaction, BD, Diagnosis, Growth, PCR, Patient, Prevalence, Helmy Eltoukhy, Software, Incidence, Breast cancer, S.A, Medical imaging, Vaccine, Medical device

The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification.

Key Points: 
  • The growth in the global molecular oncology diagnostics market is expected to be driven by the rising prevalence of cancers and increased transformations in biomarker identification.
  • The rising global cancer incidence and the growing demand for early detection are expected to drive the growth of the global molecular oncology diagnostics market during the forecast period.
  • The presence of major kit and assay providers of molecular oncology diagnostics has a major impact on the market.
  • Based on products, the global molecular oncology diagnostics market is expected to be dominated by kit and assay.

BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.

Retrieved on: 
Sunday, January 22, 2023
ISIN, Partnership, Regulatory News Service, RSV, Public health, Polymerase, Molecular biology, Virus, Acquisition, Severe acute respiratory syndrome coronavirus 2, Polymerase chain reaction, BHR, Nursing, Hospital, Bronchiolitis, COVID-19, Airport, United Kingdom, PCR, Medical device, Pharmaceutical industry, Vaccine

BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.

Key Points: 
  • BIOSYNEX SA: Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.
  • Extension of the distribution agreement between Credo Diagnostics Biomedical Pte Ltd and BIOSYNEX S.A.
    BIOSYNEX (ISIN : FR0011005933, Mnémonique :ALBIO), a major player in public health, announces the extension of its partnership with the Singaporean company Credo Diagnostics Biomedical Pte Ltd (“Credo Diagnostics”).
  • BIOSYNEX and Credo Diagnostics have recently strengthened their collaboration by signing an exclusivity agreement for an extended territory including the United Kingdom.
  • Larry Abensur, Chaiman and CEO of BIOSYNEX: “Our collaboration with Credo Diagnostics has greatly contributed to making BIOSYNEX a key player in Covid-19 diagnostics in France.

Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines

Retrieved on: 
Thursday, January 5, 2023
Veterinary, Research, Infectious Diseases, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, LNP Media Group, BioRxiv, RNA transfection, Cornell University College of Veterinary Medicine, Applied Biosystems, DNA, Polymerase chain reaction, Dog, CDMO, CAR, Severe acute respiratory syndrome coronavirus 2, Veterinary medicine, Safety, Therapy, Applied DNA Sciences, Manuscript, Vaccine, PCR, LNP

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .
  • An initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022.
  • The study demonstrated safety and immunogenicity of a linearDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines.
  • Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort, which induced robust neutralizing antibody titers and cellular immune responses.

QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Medical Devices, Research, Data Analytics, Genetics, Science, Clinical Trials, Cancer, Clinical trial, Marketing, Partnership, Sequence, Precision medicine, Fatty liver disease, Biotechnology, Drug discovery, QGEN, Polymerase, Research, NGS, Helix, NASH, RWD, Polymerase chain reaction, Genomics, Risk, Liquid biopsy, Patient, NYSE, Physician, Entrepreneurship, FDA, Doctor of Philosophy, RWE, PCR, Vaccine, Medical imaging, Pharmaceutical industry, QIAGEN, MD

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.

Key Points: 
  • QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.
  • As the development of precision medicines accelerates, so does the need for companion diagnostics devices and tests detecting clinically relevant genetic abnormalities.
  • Principally used in oncology to date, companion diagnostics that employ whole exome sequencing are widely believed to have great potential in hereditary disease areas such as cardiovascular, metabolic, neuro-degenerative, and auto-immune diseases.
  • Under the agreement announced today, QIAGEN will be the exclusive marketing and contracting partner in the U.S. for Helix’s companion diagnostic services.

Mycobacterium Tuberculosis Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023
Medical Supplies, Health, Infectious Diseases, Health Technology, General Health, Pharmaceutical, Biotechnology, PCR, ELISA, Polymerase chain reaction, Diagnosis, Mycobacterium tuberculosis, Medical device, Culture, Vaccine, Pharmaceutical industry

The "Mycobacterium Tuberculosis Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mycobacterium Tuberculosis Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The publisher's Medical Devices sector report, "Mycobacterium Tuberculosis Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the Mycobacterium Tuberculosis Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Traditional diagnosis of Mycobacterial infections depends upon smear positivity in sputum samples, culture and chest radiography.
  • For rapid diagnosis, nucleic acid amplification tests such as polymerase chain reaction (PCR), immune-based assays such as enzyme-linked immunosorbent assay (ELISA), skin patch test and rapid culture systems are performed.

Minimal Residual Disease Testing Global Market Report 2022: Industry to Reach $2.3 Billion by 2027 at a 14% CAGR - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022
Health, Other Health, Government, Cancer, Region, Flow cytometry, NGS, Leukemia, USD, Neoplasm, Lymphatic system, Polymerase chain reaction, Hospital, Academic institution, Research, Growth, Patient, PCR, Pharmaceutical industry, Medical device, Lymphoma

The global minimal residual disease testing market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0% during the forecast period.

Key Points: 
  • The global minimal residual disease testing market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0% during the forecast period.
  • The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period
    The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS).
  • In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market.
  • The global minimal residual disease testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.

Helix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary Diseases

Retrieved on: 
Thursday, January 5, 2023
Cancer, Clinical trial, QIAGEN, Partnership, Precision medicine, Biotechnology, Drug discovery, PMA, QGEN, Polymerase, Research, NGS, Autoimmunity, NASH, Inflammation, Polymerase chain reaction, CLIA, Genomics, SAN, Liquid biopsy, Patient, Fatty liver disease, NYSE, Physician, Entrepreneurship, FDA, Degenerative disease, Doctor of Philosophy, Conference, Parkinson's disease, PCR, Pharmaceutical industry, Medical imaging, MD, Helix

As part of the collaboration, Helix will leverage the Helix® Laboratory Platform to develop companion diagnostics in the U.S., and QIAGEN will use the QIASeq Human Exome Kits in the rest of world.

Key Points: 
  • As part of the collaboration, Helix will leverage the Helix® Laboratory Platform to develop companion diagnostics in the U.S., and QIAGEN will use the QIASeq Human Exome Kits in the rest of world.
  • Helix will develop companion diagnostics and clinical trial assays for all phases of clinical trials, as well as commercialize single site premarket approval (PMA) companion diagnostics.
  • "This partnership represents another step toward bringing the power of companion diagnostics to hereditary diseases by powering Helix's leading products with QIAGEN's extensive pharma and biopharma relationships, NGS capabilities, and global regulatory expertise," said Thierry Bernard, Chief Executive Officer of QIAGEN.
  • A pioneer in precision medicine, QIAGEN has more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize companion diagnostic tests for their drug candidates.

Visby Medical™ Receives FDA Emergency Use Authorization for Respiratory Health Test for use in CLIA waived settings

Retrieved on: 
Tuesday, January 3, 2023
Biomedical Advanced Research and Development Authority, United States Department of Health and Human Services, Severe acute respiratory syndrome coronavirus 2, Hand, Patient, Influenza, Federal Food, Drug, and Cosmetic Act, BARDA, Food, SAN, Administration, Product life-cycle theory, Respiratory tract, Human services, Polymerase chain reaction, Visby, CDC, COVID-19, Diagnosis, Patient satisfaction, EUA, FDA, Infectious Diseases Society of America, Laboratory, Virus, Multimedia, Degenerative disease, Infection, PCR, Physician, Development, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dietary supplement, Medical device

SAN JOSE, Calif., Jan. 3, 2023 /PRNewswire/ -- Visby Medical™ announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of care test.

Key Points: 
  • SAN JOSE, Calif., Jan. 3, 2023 /PRNewswire/ -- Visby Medical™ announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of care test.
  • The Visby Medical Respiratory Health Test is a fast, polymerase chain reaction (PCR) device that detects and differentiates between upper respiratory infections caused by Influenza (Flu) A & B, and SARS-CoV-2 (COVID-19).
  • Visby Medical has received EUA from the FDA for its Respiratory Health point of care test.
  • He further added, "Use of the Visby Respiratory Health Test at the point of care in urgent care clinics and emergency rooms will transform how patients with respiratory symptoms are diagnosed and treated."

Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic With First and Only Combination COVID-19 and Flu OTC Molecular Self-Test

Retrieved on: 
Tuesday, December 6, 2022
Music recording certification, Hand, Lucira, Certification, Gold, Polymerase chain reaction, Accreditation, Hospital, AA, OTC, Trial of the century, NAAT, PCR, Infection, Urinary tract infection, Element, National Association Medical Staff Services, Observational study, Virus, COVID-19, STI, Vaccine, Pharmaceutical industry

“Effective testing is the first line of defense in managing respiratory outbreaks,” said Loch Lomond Villa Chief Executive Officer, Ms. Cindy Donovan.

Key Points: 
  • “Effective testing is the first line of defense in managing respiratory outbreaks,” said Loch Lomond Villa Chief Executive Officer, Ms. Cindy Donovan.
  • The Lucira COVID-19 & Flu Test is a NAAT test utilizing the same platform and device design as Lucira’s COVID-19 Test to provide independent diagnoses for COVID-19, Flu A, and Flu B.
  • In October of 2019, Loch Lomond Villa was awarded Gold Certification for Excellence in Person-Centered Care by Planetree International.
  • Loch Lomond Villa is one of only 90 healthcare organizations worldwide to receive the Person-Centered Care Gold Certification since the program's launch in 2007.